论文部分内容阅读
目的:评估自体CIK细胞治疗对改善化疗后晚期乳腺癌患者机体免疫力及生活质量的疗效及安全性。方法:通过开放的、非随机同期对照研究,比较自体CIK细胞治疗与一般对症治疗对化疗后晚期乳腺癌患者外周血T淋巴细胞亚群的影响,运用E-ORTC QLQ-C30生活质量测评量表分析CIK治疗前后患者生活质量改变,观察不良反应。结果:CIK治疗对化疗后晚期乳腺癌患者外周血CD3+、CD3+CD4+、CD3+CD56+T细胞亚群的升高作用优于一般对症治疗,自体CIK细胞治疗后患者临床症状、躯体功能及总健康状况较治疗前有明显改善,无严重不良反应。结论:自体CIK细胞对改善化疗后晚期乳腺癌患者机体免疫力及生活质量有较好疗效及安全性。
Objective: To evaluate the efficacy and safety of autologous CIK cell therapy in improving the immunity and quality of life of patients with advanced breast cancer after chemotherapy. METHODS: The effects of autologous CIK cell therapy and general symptomatic treatment on peripheral blood T-lymphocyte subsets in patients with advanced breast cancer after chemotherapy were compared by open and non-randomized controlled study. E-ORTC QLQ-C30 Quality of Life Scale Analysis of CIK before and after treatment of patients with changes in quality of life, adverse reactions observed. Results: The effect of CIK on the increase of peripheral blood CD3 +, CD3 + CD4 +, CD3 + CD56 + T lymphocyte subsets in patients with advanced breast cancer after chemotherapy was better than that of general symptomatic treatment. The clinical symptoms, physical function and total body volume Health status improved significantly than before treatment, no serious adverse reactions. Conclusion: CIK cells have better curative effect and safety on improving immunity and quality of life in patients with advanced breast cancer after chemotherapy.